Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2015

Open Access 01-02-2015

Melanocortin Peptides: Potential Targets in Systemic Lupus Erythematosus

Authors: Lisa Carole Loram, Melissa Elizabeth Culp, Erin Corey Connolly-Strong, Sheila Sturgill-Koszycki

Published in: Inflammation | Issue 1/2015

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease resulting in loss of self-tolerance with multiple organs, such as the kidney, skin, joints, and the central nervous system (CNS), being targeted. Numerous immunosuppressant therapies are currently being used for the treatment of SLE, but their clinical utility is somewhat variable because of the clinical heterogeneity. Melanocortins are a family of peptides derived from the common precursor protein pro-opiomelanocortin. These multifunctional peptides activate five subtypes of melanocortin receptors expressed on immune, skin, muscle, bone, and kidney cells and cells within the CNS. Melanocortin peptides have demonstrated a variety of biologic actions including immunomodulation, melanogenesis, and renoprotection. This review aims to introduce the melanocortin system and explore the mechanisms by which they may be beneficial in diseases such as SLE.
Literature
1.
Lo, M.S., and G.C. Tsokos. 2012. Treatment of systemic lupus erythematosus: New advances in targeted therapy. Annals of the New York Academy of Sciences 1247: 138–152.PubMed
2.
Stohl, W., F. Hiepe, K.M. Latinis, M. Thomas, M.A. Scheinberg, A. Clarke, et al. 2012. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis and Rheumatism 64: 2328–2337.PubMedCentralPubMed
3.
Davis, L.S., J. Hutcheson, and C. Mohan. 2011. The role of cytokines in the pathogenesis and treatment of systemic lupus erythematosus. Journal of Interferon and Cytokine Research 31: 781–789.PubMedCentralPubMed
4.
Alunno, A., E. Bartoloni, O. Bistoni, G. Nocentini, S. Ronchetti, S. Caterbi, et al. 2012. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: The old and the new. Clinical & Developmental Immunology 2012: 823085.
5.
Xing, Q., B. Wang, H. Su, J. Cui, and J. Li. 2012. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatology International 32: 949–958.PubMed
6.
Lin, J.H., J.P. Dutz, R.D. Sontheimer, and V.P. Werth. 2007. Pathophysiology of cutaneous lupus erythematosus. Clinical Reviews in Allergy and Immunology 33: 85–106.PubMed
7.
Salem, S.A., H.M. Farouk, A.A. Mostafa, I.M. Hassan, W.M. Osman, H.A. Al-Shamy, et al. 2010. Keratinocyte and lymphocyte apoptosis: Relation to disease outcome in systemic lupus erythematosus patients with and without cutaneous manifestations. European Journal of Dermatology 20: 35–41.PubMed
8.
Hahn, B.H., M.A. McMahon, A. Wilkinson, W.D. Wallace, D.I. Daikh, J.D. Fitzgerald, et al. 2012. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care & Research (Hoboken) 64: 797–808.
9.
Nowling, T.K., and G.S. Gilkeson. 2011. Mechanisms of tissue injury in lupus nephritis. Arthritis Research & Therapy 13: 250.
10.
Sanna, G., M.L. Bertolaccini, and M.A. Khamashta. 2008. Neuropsychiatric involvement in systemic lupus erythematosus: Current therapeutic approach. Current Pharmaceutical Design 14: 1261–1269.PubMed
11.
Trysberg, E., K. Nylen, L.E. Rosengren, and A. Tarkowski. 2003. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis and Rheumatism 48: 2881–2887.PubMed
12.
Brzoska, T., T.A. Luger, C. Maaser, C. Abels, and M. Bohm. 2008. Alpha-melanocyte-stimulating hormone and related tripeptides: Biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews 29: 581–602.PubMed
13.
Catania, A. 2010. Melanocortins: Multiple actions and therapeutic potential. New York, Austin, Tex.: Springer Science+Business Media; Landes Bioscience, 153.
14.
Si, J., Y. Ge, S. Zhuang, L. Juan Wang, S. Chen, and R. Gong. 2013. Adrenocorticotropic hormone ameliorates acute kidney injury by steroidogenic-dependent and -independent mechanisms. Kidney International 83: 635–646.PubMedCentralPubMed
15.
Catania, A. 2007. The melanocortin system in leukocyte biology. Journal of Leukocyte Biology 81: 383–392.PubMed
16.
Bohm, M., J. Ehrchen, and T.A. Luger. 2012. Beneficial effects of the melanocortin analogue Nle(4)-d-Phe(7)-alpha-MSH in acne vulgaris. Journal of the European Academy of Dermatology and Venereology 28: 108–111.PubMed
17.
Konig, S., T.A. Luger, and T.E. Scholzen. 2006. Monitoring neuropeptide-specific proteases: Processing of the proopiomelanocortin peptides adrenocorticotropin and alpha-melanocyte-stimulating hormone in the skin. Experimental Dermatology 15: 751–761.PubMed
18.
Schioth, H.B., R. Muceniece, M. Larsson, F. Mutulis, M. Szardenings, P. Prusis, et al. 1997. Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes. European Journal of Pharmacology 319: 369–373.PubMed
19.
Mountjoy, K.G., L.S. Robbins, M.T. Mortrud, and R.D. Cone. 1992. The cloning of a family of genes that encode the melanocortin receptors. Science 257: 1248–1251.PubMed
20.
Abdel-Malek, Z., M.C. Scott, I. Suzuki, A. Tada, S. Im, L. Lamoreux, et al. 1992. The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation. Pigment Cell Research 13(Suppl 8): 156–162.
21.
Chan, L.F., L.A. Metherell, and A.J. Clark. 2011. Effects of melanocortins on adrenal gland physiology. European Journal of Pharmacology 660: 171–180.PubMed
22.
Magenis, R.E., L. Smith, J.H. Nadeau, K.R. Johnson, K.G. Mountjoy, and R.D. Cone. 1994. Mapping of the ACTH, MSH, and neural (MC3 and MC4) melanocortin receptors in the mouse and human. Mammalian Genome 5: 503–508.PubMed
23.
Mountjoy, K.G., M.T. Mortrud, M.J. Low, R.B. Simerly, and R.D. Cone. 1994. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Molecular Endocrinology 8: 1298–1308.PubMed
24.
Lasaga, M., L. Debeljuk, D. Durand, T.N. Scimonelli, and C. Caruso. 2008. Role of alpha-melanocyte stimulating hormone and melanocortin 4 receptor in brain inflammation. Peptides 29: 1825–1835.PubMed
25.
Catania, A., S. Gatti, G. Colombo, and J.M. Lipton. 2004. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews 56: 1–29.PubMed
26.
Sarkar, S., G. Legradi, and R.M. Lechan. 2002. Intracerebroventricular administration of alpha-melanocyte stimulating hormone increases phosphorylation of CREB in TRH- and CRH-producing neurons of the hypothalamic paraventricular nucleus. Brain Research 945: 50–59.PubMed
27.
Busca, R., and R. Ballotti. 2000. Cyclic AMP a key messenger in the regulation of skin pigmentation. Pigment Cell Research 13: 60–69.PubMed
28.
Manna, S.K., and B.B. Aggarwal. 1998. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. Journal of Immunology 161: 2873–2880.
29.
Mandrika, I., R. Muceniece, and J.E. Wikberg. 2001. Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: Evidence for dual mechanisms of action. Biochemical Pharmacology 61: 613–621.PubMed
30.
Chai, B., J.Y. Li, W. Zhang, J.B. Ammori, and M.W. Mulholland. 2007. Melanocortin-3 receptor activates MAP kinase via PI3 kinase. Regulatory Peptides 139: 115–121.PubMed
31.
Buggy, J.J. 1998. Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. Biochemical Journal 331(Pt 1): 211–216.PubMedCentralPubMed
32.
Hofland, J., P.J. Delhanty, J. Steenbergen, L.J. Hofland, P.M. van Koetsveld, F.H. van Nederveen, et al. 2012. Melanocortin 2 receptor-associated protein (MRAP) and MRAP2 in human adrenocortical tissues: Regulation of expression and association with ACTH responsiveness. Journal of Clinical Endocrinology and Metabolism 97: E747–E754.PubMed
33.
Carey, R.A., A.M. Harvey, and J.E. Howard. 1950. The effect of adrenocorticotropic hormone (ACTH) and cortisone on the course of disseminated lupus erythematosus and peri-arteritis nodosa. Bulletin of the Johns Hopkins Hospital 87: 425–460.PubMed
34.
Soffer, L.J., and R. Bader. 1952. Corticotropin and cortisone in acute disseminated lupus erythematosus; results of long-term use. Journal of the American Medical Association 149: 1002–1008.PubMed
35.
Lipton, J.M., G. Ceriani, A. Macaluso, D. McCoy, K. Carnes, J. Biltz, et al. 1994. Antiinflammatory effects of the neuropeptide alpha-MSH in acute, chronic, and systemic inflammation. Annals of the New York Academy of Sciences 741: 137–148.PubMed
36.
Lipton, J.M., and A. Catania. 1997. Anti-inflammatory actions of the neuroimmunomodulator alpha-MSH. Immunology Today 18: 140–145.PubMed
37.
Kaneva, M.K., M.J. Kerrigan, P. Grieco, G.P. Curley, I.C. Locke, and S.J. Getting. 2012. Chondroprotective and anti-inflammatory role of melanocortin peptides in TNF-alpha activated human C-20/A4 chondrocytes. British Journal of Pharmacology 167: 67–79.PubMedCentralPubMed
38.
Capsoni, F., A.M. Ongari, E. Reali, and A. Catania. 2009. Melanocortin peptides inhibit urate crystal-induced activation of phagocytic cells. Arthritis Research & Therapy 11: R151.
39.
Delgado, R., A. Carlin, L. Airaghi, M.T. Demitri, L. Meda, D. Galimberti, et al. 1998. Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. Journal of Leukocyte Biology 63: 740–745.PubMed
40.
Grabbe, S., R.S. Bhardwaj, K. Mahnke, M.M. Simon, T. Schwarz, and T.A. Luger. 1996. alpha-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. Journal of Immunology 156: 473–478.
41.
Adachi, S., T. Nakano, H. Vliagoftis, and D.D. Metcalfe. 1999. Receptor-mediated modulation of murine mast cell function by alpha-melanocyte stimulating hormone. Journal of Immunology 163: 3363–3368.
42.
Taylor, A.W., J.W. Streilein, and S.W. Cousins. 1994. Alpha-melanocyte-stimulating hormone suppresses antigen-stimulated T cell production of gamma-interferon. Neuroimmunomodulation 1: 188–194.PubMed
43.
Manna, S.K., A. Sarkar, and Y. Sreenivasan. 2006. Alpha-melanocyte-stimulating hormone down-regulates CXC receptors through activation of neutrophil elastase. European Journal of Immunology 36: 754–769.PubMed
44.
Auriemma, M., T. Brzoska, L. Klenner, V. Kupas, T. Goerge, M. Voskort, et al. 2012. alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation. Journal of Investigative Dermatology 132: 1814–1824.PubMed
45.
Becher, E., K. Mahnke, T. Brzoska, D.H. Kalden, S. Grabbe, and T.A. Luger. 1999. Human peripheral blood-derived dendritic cells express functional melanocortin receptor MC-1R. Annals of the New York Academy of Sciences 885: 188–195.PubMed
46.
Bhardwaj, R., E. Becher, K. Mahnke, M. Hartmeyer, T. Schwarz, T. Scholzen, et al. 1997. Evidence for the differential expression of the functional alpha-melanocyte-stimulating hormone receptor MC-1 on human monocytes. Journal of Immunology 158: 3378–3384.
47.
Rennalls, L.P., T. Seidl, J.M. Larkin, C. Wellbrock, M.E. Gore, T. Eisen, et al. 2010. The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells. Immunology 129: 610–619.PubMedCentralPubMed
48.
Scholzen, T.E., C. Sunderkotter, D.H. Kalden, T. Brzoska, M. Fastrich, T. Fisbeck, et al. 2003. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 144: 360–370.PubMed
49.
Brzoska, T., D. Kalden, M. Fastrich, M. Moller, H. Schioth, J. Wikkberg, et al. 1999. Two new a-melanocyte stimulating hormone (a-MSH) analogues (MS05 and MS09) are potent immunomodulators in vivo and in vitro. J Investigational Dermatology 113: 482.
50.
Rinne, P., W. Nordlund, I. Heinonen, A.M. Penttinen, A. Saraste, S.T. Ruohonen, et al. 2013. alpha-Melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction. Cardiovascular Research 97: 360–368.PubMedCentralPubMed
51.
Rajora, N., G. Boccoli, A. Catania, and J.M. Lipton. 1997. alpha-MSH modulates experimental inflammatory bowel disease. Peptides 18: 381–385.PubMed
52.
Galimberti, D., P. Baron, L. Meda, E. Prat, E. Scarpini, R. Delgado, et al. 1999. Alpha-MSH peptides inhibit production of nitric oxide and tumor necrosis factor-alpha by microglial cells activated with beta-amyloid and interferon gamma. Biochemical and Biophysical Research Communications 263: 251–256.PubMed
53.
Caruso, C., D. Durand, H.B. Schioth, R. Rey, A. Seilicovich, and M. Lasaga. 2007. Activation of melanocortin 4 receptors reduces the inflammatory response and prevents apoptosis induced by lipopolysaccharide and interferon-gamma in astrocytes. Endocrinology 148: 4918–4926.PubMed
54.
Nicolaou, A., S.E. Estdale, M. Tsatmali, D.P. Herrero, and A.J. Thody. 2004. Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone. FEBS Letters 570: 223–226.PubMed
55.
Yoon, S.W., J.S. Chun, M.H. Sung, J.Y. Kim, and H. Poo. 2008. alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthritis and Cartilage 16: 115–124.PubMed
56.
Leoni, G., H.B. Patel, A.L. Sampaio, F.N. Gavins, J.F. Murray, P. Grieco, et al. 2008. Inflamed phenotype of the mesenteric microcirculation of melanocortin type 3 receptor-null mice after ischemia-reperfusion. FASEB Journal 22: 4228–4238.PubMedCentralPubMed
57.
Taylor, A.W. 2005. The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages. Journal of Neuroimmunology 162: 43–50.PubMed
58.
Sarkar, A., Y. Sreenivasan, and S.K. Manna. 2003. alpha-Melanocyte-stimulating hormone inhibits lipopolysaccharide-induced biological responses by downregulating CD14 from macrophages. FEBS Letters 553: 286–294.PubMed
59.
Bhardwaj, R.S., A. Schwarz, E. Becher, K. Mahnke, Y. Aragane, T. Schwarz, et al. 1996. Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes. Journal of Immunology 156: 2517–2521.
60.
Taylor, A., and K. Namba. 2001. In vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH). Immunology and Cell Biology 79: 358–367.PubMed
61.
Kokot, A., A. Sindrilaru, M. Schiller, C. Sunderkotter, C. Kerkhoff, B. Eckes, et al. 2009. alpha-melanocyte-stimulating hormone suppresses bleomycin-induced collagen synthesis and reduces tissue fibrosis in a mouse model of scleroderma: Melanocortin peptides as a novel treatment strategy for scleroderma? Arthritis and Rheumatism 60: 592–603.PubMed
62.
Bitto, A., F. Polito, N. Irrera, M. Calo, L. Spaccapelo, H.R. Marini, et al. 2012. Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*. Critical Care Medicine 40: 945–951.PubMed
63.
Ottani, A., M. Galantucci, E. Ardimento, L. Neri, F. Canalini, A. Calevro, et al. 2013. Modulation of the JAK/ERK/STAT signaling in melanocortin-induced inhibition of local and systemic responses to myocardial ischemia/reperfusion. Pharmacological Research 72: 1–8.PubMed
64.
Henri, P., S. Beaumel, A. Guezennec, C. Poumes, P.E. Stoebner, M.J. Stasia, et al. 2012. MC1R expression in HaCaT keratinocytes inhibits UVA-induced ROS production via NADPH oxidase- and cAMP-dependent mechanisms. Journal of Cellular Physiology 227: 2578–2585.PubMed
65.
Muffley, L.A., K.Q. Zhu, L.H. Engrav, N.S. Gibran, and A.M. Hocking. 2011. Spatial and temporal localization of the melanocortin 1 receptor and its ligand alpha-melanocyte-stimulating hormone during cutaneous wound repair. Journal of Histochemistry and Cytochemistry 59: 278–288.PubMedCentralPubMed
66.
Slominski, A., and J. Wortsman. 2000. Neuroendocrinology of the skin. Endocrine Reviews 21: 457–487.PubMed
67.
Bohm, M., M. Raghunath, C. Sunderkotter, M. Schiller, S. Stander, T. Brzoska, et al. 2004. Collagen metabolism is a novel target of the neuropeptide alpha-melanocyte-stimulating hormone. Journal of Biological Chemistry 279: 6959–6966.PubMed
68.
Lindskog, A., K. Ebefors, M.E. Johansson, B. Stefansson, A. Granqvist, M. Arnadottir, et al. 2010. Melanocortin 1 receptor agonists reduce proteinuria. Journal of the American Society of Nephrology 21: 1290–1298.PubMedCentralPubMed
69.
Benjamins, J.A., L. Nedelkoska, B. Bealmear, and R.P. Lisak. 2013. ACTH protects mature oligodendroglia from excitotoxic and inflammation-related damage in vitro. Glia 61: 1206–1217.PubMed
70.
Caruso, C.M., L. Carniglia, D. Durand, T.N. Scimonelli, and M. Lasaga. 2013. Astrocytes: New targets of melanocortin 4 receptor actions. Journal of Molecular Endocrinology 51: R33–R50.PubMed
71.
Caruso, C., C. Mohn, A.L. Karara, V. Rettori, H. Watanobe, H.B. Schioth, et al. 2004. Alpha-melanocyte-stimulating hormone through melanocortin-4 receptor inhibits nitric oxide synthase and cyclooxygenase expression in the hypothalamus of male rats. Neuroendocrinology 79: 278–286.PubMed
72.
Berg, A.L., and P. Nilsson-Ehle. 1996. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney International 50: 538–542.PubMed
73.
Berg, A.L., P. Nilsson-Ehle, and M. Arnadottir. 1999. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney International 56: 1534–1543.PubMed
74.
Berg, A.L., P. Hansson, and P. Nilsson-Ehle. 1991. ACTH 1–24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men. Journal of Internal Medicine 229: 201–203.PubMed
75.
Berg, A.L., and P. Nilsson-Ehle. 1994. Direct effects of corticotropin on plasma lipoprotein metabolism in man—studies in vivo and in vitro. Metabolism 43: 90–97.PubMed
76.
Montero-Melendez, T., H.B. Patel, M. Seed, S. Nielsen, T.E. Jonassen, and M. Perretti. 2011. The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties. American Journal of Pathology 179: 259–269.PubMedCentralPubMed
77.
78.
Decker, D., C. Grant, L. Oh, P. Becker, D. Young, and S. Jordan. 2014. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus. Lupus 23: 802–812.PubMed
79.
Pranzatelli, M.R., E.D. Tate, N.R. McGee, A.L. Travelstead, J.A. Colliver, J.M. Ness, et al. 2013. BAFF/APRIL system in pediatric OMS: Relation to severity, neuroinflammation, and immunotherapy. Journal of Neuroinflammation 10: 10.PubMedCentralPubMed
80.
Taylor, A.W., and D.J. Lee. 2011. The alpha-melanocyte stimulating hormone induces conversion of effector T cells into Treg cells. Journal of Transplantation 2011: 246856.PubMedCentralPubMed
81.
McMahon, M., B.H. Hahn, and B.J. Skaggs. 2011. Systemic lupus erythematosus and cardiovascular disease: Prediction and potential for therapeutic intervention. Expert Review of Clinical Immunology 7: 227–241.PubMedCentralPubMed
82.
He, X., P. Xue, X. Xu, G. Luo, G. Zhou, P. Nilsson-Ehle, et al. 2006. Short-term administration of ACTH improves plasma lipid profile and renal function in kidney transplant patients. Transplantation Proceedings 38: 1371–1374.PubMed
83.
Berg, A.L., A.T. Rafnsson, M. Johannsson, J. Dallongeville, and M. Arnadottir. 2006. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins. Metabolism 55: 1083–1087.PubMed
84.
Bhardwaj, R.S., and T.A. Luger. 1994. Proopiomelanocortin production by epidermal cells: Evidence for an immune neuroendocrine network in the epidermis. Archives for Dermatological Research Archiv für Dermatologische Forschung 287: 85–90.
85.
Luger, T.A., R.S. Bhardwaj, S. Grabbe, and T. Schwarz. 1996. Regulation of the immune response by epidermal cytokines and neurohormones. Journal of Dermatological Science 13: 5–10.PubMed
86.
Kadekaro, A.L., R. Kavanagh, H. Kanto, S. Terzieva, J. Hauser, N. Kobayashi, et al. 2005. alpha-Melanocortin and endothelin-1 activate antiapoptotic pathways and reduce DNA damage in human melanocytes. Cancer Research 65: 4292–4299.PubMed
87.
Bohm, M., U. Schulte, H. Kalden, and T.A. Luger. 1999. Alpha-melanocyte-stimulating hormone modulates activation of NF-kappa B and AP-1 and secretion of interleukin-8 in human dermal fibroblasts. Annals of the New York Academy of Sciences 885: 277–286.PubMed
88.
Chen, W., J. Li, H. Qu, Z. Song, Z. Yang, J. Huo, et al. 2013. The melanocortin 1 receptor (MC1R) inhibits the inflammatory response in Raw 264.7 cells and atopic dermatitis (AD) mouse model. Molecular Biology Reports 40: 1987–1996.PubMed
89.
Etori, M., K. Yonekubo, E. Sato, K. Mizukami, K. Hirahara, H. Karasuyama, et al. 2012. Melanocortin receptors 1 and 5 might mediate inhibitory effects of alpha-melanocyte-stimulating hormone on antigen-induced chronic allergic skin inflammation in IgE transgenic mice. Journal of Investigative Dermatology 132: 1925–1927.PubMed
90.
Weening, J.J., V.D. D’Agati, M.M. Schwartz, S.V. Seshan, C.E. Alpers, G.B. Appel, et al. 2004. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology 15: 241–250.PubMed
91.
Moustafa, F.E., N.A. Soliman, A.M. Bakr, and I.M. El Shwaf. 2014. Assessment of detached podocytes in the Bowman’s space as a marker of disease activity in lupus nephritis. Lupus 23: 146–150.PubMed
92.
Berg, A.L., and M. Arnadottir. 2004. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrology, Dialysis, Transplantation 19: 1305–1307.PubMed
93.
Ponticelli, C., P. Passerini, M. Salvadori, C. Manno, B.F. Viola, S. Pasquali, et al. 2006. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. American Journal of Kidney Diseases 47: 233–240.PubMed
94.
Gong, R. 2012. The renaissance of corticotropin therapy in proteinuric nephropathies. Nature Reviews Nephrology 8: 122–128.
95.
Botte, D.A., I.L. Noronha, D.M. Malheiros, T.V. Peixoto, and S.B. de Mello. 2014. Alpha-melanocyte stimulating hormone ameliorates disease activity in an induced murine lupus-like model. Clinical and Experimental Immunology 177: 381–390.PubMed
96.
Gong, R. 2014. Leveraging melanocortin pathways to treat glomerular diseases. Advances in Chronic Kidney Disease 21: 134–151.PubMed
97.
Arnason, B.G., R. Berkovich, A. Catania, R.P. Lisak, and M. Zaidi. 2013. Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Multiple Sclerosis 19: 130–136.PubMedCentralPubMed
98.
Huang, Q.H., M.L. Entwistle, J.D. Alvaro, R.S. Duman, V.J. Hruby, and J.B. Tatro. 1997. Antipyretic role of endogenous melanocortins mediated by central melanocortin receptors during endotoxin-induced fever. Journal of Neuroscience 17: 3343–3351.PubMed
99.
Sinha, P.S., H.B. Schioth, and J.B. Tatro. 2003. Activation of central melanocortin-4 receptor suppresses lipopolysaccharide-induced fever in rats. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 284: R1595–R1603.PubMed
100.
Tatro, J.B., and P.S. Sinha. 2003. The central melanocortin system and fever. Annals of the New York Academy of Sciences 994: 246–257.PubMed
101.
Catania, A., and J.M. Lipton. 1993. alpha-Melanocyte stimulating hormone in the modulation of host reactions. Endocrine Reviews 14: 564–576.PubMed
102.
Lipton, J.M., J.R. Glyn, and J.A. Zimmer. 1981. ACTH and alpha-melanotropin in central temperature control. Federation Proceedings 40: 2760–2764.PubMed
103.
Ahmed, T.J., T. Montero-Melendez, M. Perretti, and C. Pitzalis. 2013. Curbing inflammation through endogenous pathways: Focus on melanocortin peptides. International Journal of Inflammation 2013: 985815.PubMedCentralPubMed
Metadata
Title
Melanocortin Peptides: Potential Targets in Systemic Lupus Erythematosus
Authors
Lisa Carole Loram
Melissa Elizabeth Culp
Erin Corey Connolly-Strong
Sheila Sturgill-Koszycki
Publication date
01-02-2015
Publisher
Springer US
Published in
Inflammation / Issue 1/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0029-5

Other articles of this Issue 1/2015

Inflammation 1/2015 Go to the issue

OriginalPaper

Association of Transforming Growth Factor-Beta 1 Promoter Variant -509 C/T with Bronchial Asthma in South Indian Population

OriginalPaper

NS5ATP9 Suppresses Activation of Human Hepatic Stellate Cells, Possibly via Inhibition of Smad3/Phosphorylated-Smad3 Expression

OriginalPaper

Lapatinib Ameliorates Experimental Arthritis in Rats

OriginalPaper

Anti-Inflammatory and Membrane-Stabilizing Properties of Two Semisynthetic Derivatives of Oleanolic Acid

OriginalPaper

Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever

OriginalPaper

Pemetrexed Ameliorates Experimental Arthritis in Rats
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits